InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -230.00% | -1.37% | -410.53% | 60.69% | -186.05% |
| Total Depreciation and Amortization | 22.22% | -10.00% | 66.67% | -33.33% | -10.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 217.92% | -27.59% | 306.53% | -150.57% | 6,653.85% |
| Change in Net Operating Assets | -125.37% | 2,521.74% | -52.08% | 103.00% | -607.94% |
| Cash from Operations | -96.79% | 86.41% | 173.02% | 49.75% | -248.59% |
| Capital Expenditure | -300.00% | 80.00% | -25.00% | 33.33% | -100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -200.00% | -98.55% | -- | -- |
| Cash from Investing | -100.00% | 50.00% | -106.15% | 1,183.33% | -100.00% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 25.00% | 0.00% | 33.33% | 0.00% | -20.00% |
| Issuance of Common Stock | -100.00% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -82.22% | -31.95% | 12.55% | -- |
| Cash from Financing | -101.96% | -84.64% | 149.00% | -53.43% | 17,280.00% |
| Foreign Exchange rate Adjustments | -100.00% | 1,866.67% | 70.00% | -155.56% | 124.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -98.31% | -34.41% | 2,869.39% | 62.88% | -122.22% |